DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months
ECCO'20 Vienna
2020
DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine
ECCO'20 Vienna
2020
DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study
ECCO'20 Vienna
2020
DOP22 Certification of integral care IBD Units: Evaluation of a certification program (CUE)
ECCO'20 Vienna
2020
DOP23 Endoscopic evaluation at 1 month after ileocolic resection for Crohn’s disease predicts postoperative recurrence and is safe
ECCO'20 Vienna
2020
DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial
ECCO'20 Vienna
2020
DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort
ECCO'20 Vienna
2020
DOP26 Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease
ECCO'20 Vienna
2020
DOP27 Transanal minimally invasive surgery (TAMIS): A novel approach for treatment of pouch failure
ECCO'20 Vienna
2020
DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: A pilot serum proteomic analysis of the PANTS cohort
ECCO'20 Vienna
2020
DOP30 Multi-‘omics profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse
ECCO'20 Vienna
2020
DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches
ECCO'20 Vienna
2020
DOP34 Transplantation of human intestine into the mouse: A novel platform for study of inflammatory enterocutaneous fistulas
ECCO'20 Vienna
2020
DOP35 Monitoring of mucosal T cells subsets under biotherapies in IBD: responders exhibit a phenotype similar to healthy controls
ECCO'20 Vienna
2020
DOP36 Family-specific host genetic and gut microbial signatures have a beneficial role in early identification of familial inflammatory bowel diseases
ECCO'20 Vienna
2020